Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 20.84 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; light magnesium oxide; microcrystalline cellulose; crospovidone; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - btc rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events btc rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). btc rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia btc rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with btc rosuvastatin , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 41.68 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; lactose; light magnesium oxide; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; sunset yellow fcf aluminium lake; triacetin; brilliant blue fcf aluminium lake; allura red ac aluminium lake - btc rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events btc rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). btc rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia btc rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with btc rosuvastatin , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 10.42 mg - tablet, film coated - excipient ingredients: magnesium stearate; light magnesium oxide; lactose; microcrystalline cellulose; crospovidone; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - rosintas should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events rosintas is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosintas is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosintas is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with rosintas , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 5.21 mg - tablet, film coated - excipient ingredients: lactose; microcrystalline cellulose; magnesium stearate; crospovidone; light magnesium oxide; hypromellose; triacetin; titanium dioxide; lactose monohydrate; iron oxide yellow - btc rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events btc rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). btc rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia btc rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with btc rosuvastatin , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - sodium fusidate -

Australia - English - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - sodium fusidate, quantity: 20 mg/g - ointment - excipient ingredients: white soft paraffin; cetyl alcohol; wool fat; liquid paraffin - skin lesions primarily and secondarily infected with staphylococci, e.g. abscesses, boils, furunculosis, impetigo, folliculitis, hidradenitis, pyoderma, sycosis barbae, otitis externa.

Ireland - English - HPRA (Health Products Regulatory Authority)

leo pharma a/s - sodium fusidate - impregnated dressing - 30 milligram(s) - medicated dressings with antiinfectives; fusidic acid - medicated dressings with antiinfectives - fucidin is indicated for the treatment of skin infections caused by bacteria susceptible to sodium fusidate in children from 1 year of age and adults. consideration should be given to official guidance on the appropriate use of antibacterial agents. prescribers should consider local resistance and susceptibility.

Canada - English - Health Canada

jamp pharma corporation - atorvastatin (atorvastatin calcium) - tablet - 10mg - atorvastatin (atorvastatin calcium) 10mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

jamp pharma corporation - atorvastatin (atorvastatin calcium) - tablet - 20mg - atorvastatin (atorvastatin calcium) 20mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

jamp pharma corporation - atorvastatin (atorvastatin calcium) - tablet - 40mg - atorvastatin (atorvastatin calcium) 40mg - hmg-coa reductase inhibitors